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rokinase-type plasminogen activator (uPA) and its
 
receptor (uPAR) play an important role in cell guidance
and chemotaxis during normal and pathological
events. uPAR is GPI-anchored and the mechanism by
which it transmits intracellular polarity cues across the
plasma membrane during directional sensing has not been
elucidated. The constitutively recycling endocytic receptor
Endo180 forms a trimolecular complex with uPAR in the
presence of uPA, hence its alternate name uPAR-associated
protein. Here, we demonstrate that Endo180 is a general
U
 
promoter of random cell migration and has a more specific
function in cell chemotaxis up a uPA gradient. Endo180
expression was demonstrated to enhance uPA-mediated
filopodia production and promote rapid activation of
Cdc42 and Rac. Expression of a noninternalizing Endo180
mutant revealed that promotion of random cell migration
requires receptor endocytosis, whereas the chemotactic
response to uPA does not. From these studies, we conclude
that Endo180 is a crucial link between uPA–uPAR and setting
of the internal cellular compass.
 
Introduction
 
Chemotaxis is the mechanism that ensures guided relocalization
of cells from one site to another and is pivotal within a
plethora of biological and pathological processes (Parent and
Devreotes, 1999; Jones, 2000; Baggiolini, 2001; Bourne and
Weiner, 2002; Weiner, 2002), including the dissemination
of tumor cells in malignant disease (Moore, 2001; Muller et
al., 2001). For such polarized motility, cell surface receptors
must sense directional signals in the external environment
and activate the intracellular chemosensory machinery. If
the necessary polarity cues are absent or not activated, a cell
can only migrate in random directions.
Urokinase-type plasminogen activator (uPA) and its re-
ceptor uPAR are strongly linked to cancer cell chemotaxis
during invasion and metastasis (Ossowski and Aguirre-
Ghiso, 2000; Preissner et al., 2000; Mazar, 2001) and in
this scenario uPAR has multiple functions. In particular,
uPAR can focus and regulate the proteolytic activity of uPA
at the plasma membrane. More intriguingly, uPAR acts as a
central cell surface coordinator that transmits migratory and
polarity cues into the cell. Because uPAR is a GPI-anchored
receptor, its association with transmembrane coreceptors
is required for this latter function as well as for the inter-
nalization of uPA–uPAR (Blasi and Carmeliet, 2002).
Endo180 was recently identified in chemical cross-linking
studies as part of a trimolecular cell surface complex with
uPA and uPAR (Behrendt et al., 2000). This 180-kD trans-
membrane glycoprotein is one of the four members of the
mannose receptor family (East and Isacke, 2002) and in
common with other family members is a constitutively re-
cycling endocytic receptor (Isacke et al., 1990; Howard
and Isacke, 2002). Commensurate with its role as a uPAR
coreceptor, Endo180 expression in normal tissue is re-
stricted to stromal cells, macrophages, a subset of endothe-
lial cells, and sites of chondrogenic/osteogenic activity with
a marked increase in expression in tumor endothelium and
breast cancer tissue (Blasi, 1993; East and Isacke, 2002;
Schnack Nielsen et al., 2002). Here, we directly addressed
the question as to whether Endo180 can regulate uPA–uPAR
mediated cell chemotaxis.
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Results and discussion
 
For initial studies, the MDA-MB-231 breast cancer cells
were used as they express Endo180, uPAR and EGF recep-
tor, and respond chemotactically to uPA and EGF (Sturge et
al., 2002). The staining of Endo180 in MDA-MB-231 cells
(Fig. 1) is consistent with previous reports that 10–30% of
this receptor is in clathrin-coated pits at the cell surface,
whereas 70–90% is located in endosomal compartments
(Isacke et al., 1990; Howard and Isacke, 2002). uPAR is also
detected in a clustered distribution, although it has a limited
overlap with Endo180. Upon uPA stimulation, which is
known to promote uPA–uPAR-Endo180 complex forma-
tion (Behrendt et al., 2000), Endo180 and uPAR are trans-
located to the leading edge of polarized cells where they dis-
play a substantial degree of colocalization (Fig. 1). To
directly investigate the role of Endo180 in these cells, a small
interfering RNA (siRNA) approach was taken. Endo180
siRNA treatment resulted in a marked reduction in
Endo180 expression (Fig. 2 A; see Fig. 4 C) but did not alter
uPAR levels (Fig. 2 A), indicating that expression of these
two receptors is not coordinately regulated at the cell sur-
face. This down-regulation of Endo180 had no effect on the
basal migratory speed of unstimulated cells but significantly
(P 
 
 
 
0.001) reduced the motility of cells in response to uPA
or EGF, or when cultured in the presence of a growth factor
cocktail (Fig. 2 B). This suggests a general role for Endo180
in the motility of cells stimulated by pro-migratory factors.
The most striking alteration in the behavior of Endo180
siRNA treated cells was in their differential ability to re-
spond directionally in chemotactic gradients of uPA and
EGF. As expected from previous studies (Sturge et al.,
2002), untreated (not depicted) or control siRNA treated
MDA-MB-231 cells migrated directionally up gradients of
uPA (Fig. 2 C; Video 1, available at http://www.jcb.org/cgi/
content/full/jcb.200302124/DC1) and EGF (Fig. 2 C).
Endo180 siRNA treatment significantly inhibited the che-
Figure 1. Endogenous Endo180 and uPAR colocalize in response 
to uPA stimulation. MDA-MB-231 cells were stimulated with or 
without uPA for 30 min, fixed, permeabilized, and stained. Notably 
the colocalization of uPAR and Endo180 rich clusters in uPA-stimulated 
cells occurs in areas of new actin polymerization and membrane 
ruffling (as determined by costaining of uPAR or Endo180 with 
phalloidin; not depicted). Bar, 20 m. Asterisk indicates area of 
interest magnified five times and shown in inset.
Figure 2. Endo180 is a general requirement for growth factor–
stimulated cell motility but a specific promoter of directionality 
up a uPA gradient. MDA-MB-231 cells were incubated with control 
or Endo180 siRNA oligonucleotides or left untreated and analyzed 
after 48 h. (A) FACS® analysis of Endo180 and uPAR expression 
levels in control (green) and Endo180 (red) siRNA treated cells. Black 
lines show binding of second antibody alone to control siRNA 
treated cells. Endo180 expression in control siRNA treated cells was 
identical to that in untreated cells (not depicted). (B) Mean migratory 
speed of unstimulated, uPA- or EGF-stimulated cells, or cells cultured 
in growth factor cocktail (Opti-MEM medium). ct, control siRNA; 
E, Endo180 siRNA. Migratory speed values are given as the mean 
speed for all cells analyzed over the 5-h period  SEM. (C) Chemo-
tactic response of siRNA or mAb treated cells to a gradient of uPA or 
EGF. (B and C) Data shown includes analysis of 50 cells pooled 
from at least three separate experiments. (C) Cell directionality was 
determined using the Rayleigh test and a horizon distance, which 
included 50% of all cells assayed for each treatment group. Analysis 
of the same data using 85% of cells is included in Fig. S1. This highly 
stringent approach discounts any bias in the calculation of direc-
tionality that might be caused by alterations in cell speed. Mean 
direction of cell migration (red arrow)/95% confidence interval 
(green wedge). (D) Epitope mapping of anti-Endo180 mAbs. 
Endo180-Fc constructs were resolved by 10% nonreducing SDS-PAGE 
and subject to Western blotting. The schematic diagram of Endo180 
indicates mAb E1/183 binding to the cysteine-rich domain (CR) and 
mAb A51/58 binding to CTLD2.
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motactic response to uPA (Fig. 2 C; Video 2, available at
http://www.jcb.org/cgi/content/full/jcb.200302124/DC1)
but had no impact on the chemotactic response to EGF
(Fig. 2 C). To further investigate the structural interplay of
Endo180 in the uPA–uPAR specific response, chemotaxis
assays were performed in the presence of Endo180 mAbs
E1/183 and A5/158. The four members of the mannose re-
ceptor family have a common structural organization of an
NH
 
2
 
-terminal cysteine-rich domain, a fibronectin type II
domain (FNII) and 8 or 10 C-type lectin-like domains
(CTLDs), and single-particle electron microscopy has re-
vealed that in Endo180 the NH
 
2
 
-terminal domains form a
hairpin structure such that the cysteine-rich domain con-
tacts CTLD2 (Rivera-Calzada et al., 2003). mAb A5/158
binds to CTLD2 and totally blocks directional migration up
a uPA gradient, whereas mAb E1/183, which binds the cys-
teine-rich domain, partially blocks uPA-induced chemotaxis
(Fig. 2 C; Fig. S1, see supplemental methods for a full defi-
nition of total and partial blockade, and available at http://
www.jcb.org/cgi/content/full/jcb.200302124/DC1). The
isotype matched mAb B3/25, which recognizes the en-
docytic transferrin receptor, had no effect on this response
(Fig. 2 C). Together, these findings indicate that a specific
biological function of Endo180 is to regulate uPA–uPAR
mediated directionality and suggest that accessibility of
CTLD2 is required for a full biological response.
To confirm that these effects of Endo180 were not cell
type specific or an artifact of the siRNA system, stable popu-
lations of the uPAR and EGF receptor positive/Endo180
negative MCF-7 breast cancer cell line transfected with vec-
tor alone or Endo180 were generated (Fig. 3 A). In agree-
ment with the data obtained with MDA-MB-231 cells (Fig.
2 B), Endo180 expression promoted a statistically significant
(P 
 
 
 
0.0001) twofold increase in random migration com-
pared with vector-alone transfected cells (Fig. 3 B). Al-
though unstimulated parental or vector-alone transfected
MCF-7 cells produced small membrane protrusions, they
did not translocate on a Matrigel surface (Video 3, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200302124/
DC1) or a variety of other substrata including fibronectin,
collagens I and IV. In contrast, MCF-7 cells expressing
Endo180 exhibited increased membrane protrusion forma-
tion and translocated randomly on Matrigel (Video 4, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200302124/
DC1) and the other substrata tested. These observations in-
dicate that Endo180 is both necessary and sufficient to
evoke motility in this cell type. Parental or vector-alone
transfected MCF-7 cells placed in a gradient of uPA dis-
played increased but nondirectional migration (Fig. 3, B and
C; Video 5, available at http://www.jcb.org/cgi/content/full/
jcb.200302124/DC1). The inability of vector-alone cells to
detect a chemotactic gradient was consistent at 1, 5, 10, 15,
20, and 25 nM uPA, a concentration range within which the
directional migration of MDA-MB-231 cells is maximally
stimulated (Sturge et al., 2002). In accordance with the
MDA-MB-231 cell data, MCF-7 cells expressing Endo180
were endowed with a sense of direction up a uPA gradient
(Fig. 3 C; Video 6, available at http://www.jcb.org/cgi/
content/full/jcb.200302124/DC1; P 
 
 
 
0.0001). Further-
more, this directional migration was totally inhibited by the
anti-Endo180 mAb A5/158 (Fig. 3 C) and was not associ-
ated with altered cell surface levels of uPAR (Fig. 3 A). Con-
versely, both vector-alone cells and cells expressing Endo180
displayed increased migratory speed (Fig. 3 B) and direc-
Figure 3. Expression of Endo180 is sufficient 
to confer a sense of direction up a concentration 
gradient of uPA. (A) FACS analysis of Endo180 and 
uPAR cell surface expression levels in MCF-7 cells 
transfected with vector alone (green), wild-type 
Endo180 (red), or Endo180(Ala1468/Ala1469) (blue). 
Profiles in black represent vector transfected cells 
incubated with secondary antibody alone. (B) 
Mean migratory speed of transfected MCF-7. The 
directional data are summarized in a circular 
histogram showing the number of cells lying within 
each 18 interval. The mean direction and its 95% 
confidence interval are represented as a red arrow 
and green sector, respectively. (C, D) Chemotactic 
response of untreated or mAb A5/158-treated 
transfected MCF-7 cells in a gradient of uPA or 
EGF. Data shown in B–D includes analysis of 70 
cells pooled from at least three experiments. Cell 
directionality was determined using the Rayleigh 
test and a horizon distance which included 50% of 
all cells assayed for each treatment group. (C and D) 
The directional data are summarized in a circular 
histogram showing the number of cells lying within 
each 18 degree interval. The mean direction and 
its 95% confidence interval are represented as a 
red arrow and green sector, respectively.
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tionality up an EGF gradient that was unaffected by
Endo180 mAbs (Fig. 3 D), further confirming that direc-
tional sensing of an EGF gradient is an Endo180-indepen-
dent process.
Next, we addressed the mechanism by which Endo180
modulated migratory and chemotactic responses by examin-
ing MCF-7 cells transfected with an Endo180(Ala
 
1468
 
/Ala
 
1469
 
)
construct. This mutant is expressed at the cell surface (Fig. 3
A) but is internalization defective (Howard and Isacke, 2002;
Wienke et al., 2003). In contrast to wild-type Endo180, ex-
pression of Endo180(Ala
 
1468
 
/Ala
 
1469
 
) did not increase the mi-
gratory speed of cells on Matrigel (Fig. 3 B) or other substrata
(not depicted), indicating that the random motility evoked by
Endo180 is dependent on constitutive recycling of the recep-
tor. Despite an impaired migratory speed (Fig. 3 B), cells ex-
pressing Endo180(Ala
 
1468
 
/Ala
 
1469
 
) still displayed strong direc-
tional sensing of a uPA gradient (P 
 
 
 
0.0001) and this
directionality was totally blocked by mAb A5/158 (Fig. 3 C).
Similar to cells expressing wild-type Endo180, there was little
effect of Endo180(Ala
 
1468
 
/Ala
 
1469
 
) expression on their migra-
tory speed (Fig. 3 B) or directionality (Fig. 3 D) up a gradient
of EGF or on the cell surface expression of uPAR (Fig. 3 A).
These results suggest that the ability of Endo180 to coordi-
nate the directionality of a cell toward uPA can be transduced
from its localization on the plasma membrane and is separate
from its endocytic function.
The intracellular mechanisms for generation of polarity
and migration in eukaryotic cells are beginning to be eluci-
dated. Phospholipid and small Rho GTPase signaling path-
ways converge to regulate recruitment of Arp2/3 complex by
WASP/WAVE family scaffolding proteins, which rapidly re-
arrange the actin cytoskeleton to produce structures that
change the polarity and orientation of a cell (Franz et al.,
2002; Weiner, 2002). Much less is understood about how
extracellular signals are linked to this intracellular machinery.
To further elucidate the mechanism of Endo180-dependent
chemotaxis, the effect of altered Endo180 expression on the
temporal activation of the Rho-family GTPases Cdc42, Rac
and RhoA was examined. These molecular switches have
fundamental roles in cell migration and chemotaxis (Nobes
and Hall, 1995; Allen et al., 1998; Jones, 2000) and their de-
regulation is strongly implicated in metastasis (Jaffe and
Hall, 2002; Sahai and Marshall, 2002). More importantly,
Rac and Cdc42 can regulate cell motility downstream of
uPAR (Kjoller and Hall, 2001; Sturge et al., 2002). In
Endo180, but not vector-alone, expressing MCF-7 cells uPA
stimulation increased filopodia production (Fig. 4 A) and
caused rapid and sustained activation of Cdc42 (Fig. 4 B).
Consistent with these findings, uPA-stimulated activation of
Cdc42 in MDA-MB-231 cells was blocked by Endo180
siRNA, but not control siRNA, treatment (Fig. 4 C),
whereas EGF-stimulated Cdc42 activation was unaffected by
Endo180 siRNA treatment (Fig. 4 C). Despite an impaired
activation of Cdc42, vector alone expressing cells show a sub-
stantial activation of Rac in response to uPA, which together
may account for their increased migration without direc-
tional sensing in a uPA gradient. Although these data also
suggest that Rac activation is not dependent on Endo180,
the rapidity of uPA-dependent Rac activation in Endo180
transfected cells points to a regulatory role for this receptor in
 
stimulating Rac activity. Endo180(Ala
 
1468
 
/Ala
 
1469
 
) expression
resulted in delayed Cdc42 activation, but the level of activa-
tion stimulated by uPA was similar to that seen in Endo180
expressing cells. In contrast, Rac activation was impaired in
Endo180(Ala
 
1468
 
/Ala
 
1469
 
) expressing cells providing a molec-
ular explanation for the ability of these cells to sense a uPA
gradient without increasing their migratory speed. Based on
these results, we propose that Endo180 plays an important
regulatory role in coordinating the activation of the Cdc42
and Rac GTPases during uPA-induced chemotaxis. In agree-
ment with a previous report (Jo et al., 2002), RhoA was not
significantly activated by uPA in either the MCF-7 cell lines
or MDA-MB-231 cells (unpublished data). uPA–uPAR sig-
Figure 4. Endo180 promotes filopodia formation in response to 
uPA and promotes rapid uPA–uPAR mediated activation of Cdc42 
and Rac. (A) Endo180 transfected MCF-7 cells were stimulated 
with or without uPA for 5 min, fixed and immunostained with mAb 
A5/158 and counterstained with Alexa 555-phalloidin. Bar, 10 m. 
Quantitative values shown graphically represent mean  SEM number 
of filopodia per cell from a total of 50 randomly chosen cells in two 
independent experiments. (B) Cdc42 and Rac activation time courses 
in MCF-7 cells transfected with vector alone (green), Endo180 (red) 
or Endo180(Ala1468/Ala1469) (blue) and stimulated with uPA. Values 
represent the mean  SEM percent change from levels of vector 
alone cells at zero time point (n  4–6 experiments). Bottom panels 
show representative immunoblots. (C) Endo180 expression and 
Cdc42 activation in siRNA treated MDA-MB-231 cells stimulated 
with uPA or EGF for 5 min ct, control siRNA; E, Endo180 siRNA. 
Left panel shows representative blot, right panel shows a graphical 
representation of mean  SD percent change from levels in control 
siRNA treated cells (n  2 experiments).
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naling has been shown to activate the MAPK pathway
(Nguyen et al., 1999) and Akt (protein kinase B; Sturge et
al., 2002; Chandrasekar et al., 2003). However, wild-type
Endo180 or Endo180(Ala
 
1468
 
/Ala
 
1469
 
) expression did not al-
ter the time course of uPA-mediated extracellular signal–reg-
ulated kinase 1/2 (ERK1/2) phosphorylation in MCF-7 cells
or enhance Akt phosphorylation (Fig. 5 A).
Finally, we considered the possibility that the effect of
Endo180 on uPA-mediated cell chemotaxis might, at least in
part, result from this constitutively recycling transmembrane
receptor modulating the cell surface levels of other uPAR as-
sociated proteins. However, Endo180 expression was shown
to have no effect on plasma membrane expression of either
integrins (Wienke et al., 2003) or low density lipoprotein re-
ceptor–related protein (LRP; Fig. 5 B)–uPAR coreceptors,
which have been previously demonstrated to promote cell
signaling and migration in response to uPA stimulation.
The findings of this paper demonstrate that coexpression
of Endo180 and uPAR promotes the guided migration of
breast tumor cells. This significantly advances our under-
standing of how these receptors may participate in meta-
static spread and tumor progression. The up-regulation of
Endo180 expression in tumor endothelium (St. Croix et al.,
2000) indicates a potential role for this receptor in the regu-
lation of tumor neoangiogenesis, a process that is hallmarked
by endothelial cell chemotaxis and has a strong dependence
on the interaction between uPA and uPAR (Mazar, 2001;
Pepper, 2001). In addition to its interaction with uPA–
uPAR, Endo180 functions as a Ca
 
2
 

 
-dependent mannose
binding C-type lectin (East et al., 2002) and as a collagen
binding/internalization receptor (Behrendt et al., 2000;
Wienke et al., 2003), and binding of these ligands is medi-
ated by CTLD2 and FNII, respectively. Furthermore, the
functional interplay between the different ligand binding ac-
tivities of Endo180 predicted in a recent 3D structural
model (Rivera-Calzada et al., 2003), is evidenced by the
finding that collagens block the association with uPAR
(Behrendt et al., 2000), and as shown here, an antibody di-
rected against the sugar binding CTLD2 blocks cellular re-
sponses to uPA. What is apparent from the data presented
here is that role of Endo180 in promoting random “nondi-
rectional” cell migration (Figs. 3 and 4; East et al., 2003;
Engelholm et al., 2003) is dependent on receptor internal-
ization and thereby mechanistically distinct from the unique
function of Endo180 as a cell surface coordinator for setting
up the internal cellular compass in a gradient of uPA.
 
Materials and methods
 
Reagents and cells
 
Rabbit anti-Endo180 polyclonal antibody and anti-Endo180 mAbs A5/158
and E1/183 have been described previously (Isacke et al., 1990; Sheikh et
al., 2000). B3/25 antitransferrin receptor mAb was a gift from C. Hopkins
(Imperial College, London, UK). Mouse anti–human uPAR antibody 3936,
(America Diagnostica, Inc.), mouse anti–human-LRP (Serotec), mouse
anti–human pan-ERK1/2 (Sigma-Aldrich), mouse anti–human phospho-
ERK1/2, rabbit anti–human pan-PKB/AKT, and mouse anti–human phos-
pho-AKT (Upstate Biotechnology). Alexa555 anti–rabbit Ig, Alexa488
anti–mouse Ig and Alexa555-phalloidin (Molecular Probes), and HRP anti–
mouse Ig (Jackson ImmunoResearch Laboratories). Catalytically inactive
uPA, as used previously (Sturge et al., 2002), was a gift from J. Hamelin (In-
stitut National de la Santé et de la Recherche Medicale U461, France) and
EGF (R&D Systems) were used at 10 nM and 15 ng/ml, respectively, in all
assays. Extracellular domain Endo180 constructs truncated after the cys-
teine-rich domain, FNII, CTLD1, CTLD2, CTLD4, or CTLD8 fused in frame
with the Fc portion of human Ig were generated and expressed in COS-1
cells as described previously (East et al., 2002). MCF-7 transfectants and
siRNA treatment of MDA-MB-231 cells has been described previously
(Wienke et al., 2003; see Online supplemental material). MCF-7 cells were
maintained in DME 
 

 
 10% FCS unless otherwise stated. MDA-MB-231
cells were cultured in DME 
 

 
 10% FCS and starved in DME 
 

 
 0.1% FCS
for 24 h before analysis.
 
Cdc42, Rac, RhoA, ERK1/2, and Akt activation assays
 
MCF-7 or MDA-MB-231 cells were grown to 50% confluence and starved
for 24 h in DME before treatment. Cells were lysed in ice-cold lysis buffer
plus protease and phosphatase inhibitors. Active Cdc42, Rac, and RhoA
were measured using assay kits according to the manufacturer’s instruc-
tions (Upstate Biotechnology). ERK1/2 and Akt phosphorylation were mea-
sured by immunoblot analysis with phospho-specific antibodies.
 
Chemotaxis/migration assay
 
Chemotaxis and migration were measured by direct observation and re-
cording of cell behavior in stable concentration gradients of 10 nM uPA or
15 ng/ml EGF using the Dunn chemotaxis chamber as described previ-
ously (Allen et al., 1998; Sturge et al., 2002). Full details are provided in
Online supplemental material.
 
Online supplemental material
 
Materials and methods describing the Endo180 siRNA oligonucleotides
and methods of transfections, a detailed account of how the Dunn cham-
ber chemotaxis experiments were undertaken, and how the data is ana-
lyzed. Fig. S1 shows the same data as shown in Fig. 2 C but using a lower
stringency analysis. Videos 1–6 show examples of Dunn chamber experi-
ments. Online supplemental material is available at http://www.jcb.org/
cgi/content/full/jcb.200302124/DC1. 
 
We thank David Robertson for his help with confocal imaging, Dr. Jocelyne
Hamelin for providing us with uPA, Dr. Graham Dunn for writing the Math-
ematica™ Notebooks used to analyze the chemotaxis data, and Prof. Alan
Figure 5.  Endo189 expression does not alter ERK1/2 and Akt 
phosphorylation or cell surface LRP. (A) ERK1/2 and Akt phosphor-
ylation in MCF-7 cells transfected with vector alone, Endo180 or 
Endo180(Ala1468/Ala1469) and stimulated with uPA. Blots show 
phosphorylated ERK1/2 and Akt together with total ERK1/2 and 
Akt as loading controls. (B) FACS® analysis of LRP cell surface 
expression levels in MCF-7 cells transfected with vector alone 
(green), wild-type Endo180 (red) or Endo180(Ala1468/Ala1469) (blue). 
Profiles in black represent vector transfected cells incubated with 
secondary antibody alone.
Th
e 
Jo
ur
na
l o
f C
el
l B
io
lo
gy
 
794 The Journal of Cell Biology 
 
|
 
 
 
Volume 162, Number 5, 2003
Ashworth for his critical advice during the preparation of this manuscript. 
This work was funded by Breakthrough Breast Cancer, the Association
of International Cancer Research and The Wellcome Trust. L. East was sup-
ported by a Medical Research Council studentship.
 
Submitted: 21 February 2003
Accepted: 11 July 2003
 
References
 
Allen, W.E., D. Zicha, A.J. Ridley, and G.E. Jones. 1998. A role for Cdc42 in mac-
rophage chemotaxis. 
 
J. Cell Biol.
 
 141:1147–1157.
Baggiolini, M. 2001. Chemokines in pathology and medicine. 
 
J. Intern. Med.
 
 250:
91–104.
Behrendt, N., O.N. Jensen, L.H. Engelholm, E. Mortz, M. Mann, and K. Dano.
2000. A urokinase receptor-associated protein with specific collagen binding
properties. 
 
J. Biol. Chem.
 
 275:1993–2002.
Blasi, F. 1993. Urokinase and urokinase receptor: a paracrine/autocrine system reg-
ulating cell migration and invasiveness. 
 
Bioessays.
 
 15:105–111.
Blasi, F., and P. Carmeliet. 2002. uPAR: A versatile signalling orchestrator. 
 
Nat.
Rev. Mol. Cell Biol.
 
 3:932–943.
Bourne, H.R., and O. Weiner. 2002. A chemical compass. 
 
Nature.
 
 419:21.
Chandrasekar, N., S. Mohanam, M. Gujrati, W.C. Olivero, D.H. Dinh, and J.S.
Rao. 2003. Downregulation of uPA inhibits migration and PI3K/Akt signal-
ing in glioblastoma cells. 
 
Oncogene.
 
 22:392–400.
East, L., and C.M. Isacke. 2002. The mannose receptor family. 
 
Biochim. Biophys.
Acta.
 
 1572:364–386.
East, L., A. McCarthy, D. Wienke, J. Sturge, A. Ashworth, and C.M. Isacke. 2003.
A targeted deletion in the endocytic receptor gene Endo180 results in a de-
fect in collagen uptake. 
 
EMBO Rep.
 
 4:710–716.
East, L., S. Rushton, M.E. Taylor, and C.M. Isacke. 2002. Characterization of
sugar binding by the mannose receptor family member, Endo180. 
 
J. Biol.
Chem.
 
 277:50469–50475.
Engelholm, L.H., K. List, S. Netzel-Arnett, E. Cukierman, D.J. Mitola, H. Aaron-
 
son, L. Kjoller, J.K. Larsen, K.M. Yamada, D.K. Strickland, et al. 2003.
uPARAP/Endo180 is essential for cellular uptake of collagen and promotes
fibroblast collagen adhesion. 
 
J. Cell Biol.
 
 160:1009–1015.
Franz, C.M., G.E. Jones, and A.J. Ridley. 2002. Cell migration in development
and disease. 
 
Dev. Cell.
 
 2:153–158.
Howard, M.J., and C.M. Isacke. 2002. The C-type lectin receptor Endo180 dis-
plays internalization and recycling properties distinct from other members of
the mannose receptor family. 
 
J. Biol. Chem.
 
 277:32320–32331.
Isacke, C.M., P. Vandergeer, T. Hunter, and I.S. Trowbridge. 1990. P180, a novel
recycling transmembrane glycoprotein with restricted cell type expression.
 
Mol. Cell. Biol.
 
 10:2606–2618.
Jaffe, A.B., and A. Hall. 2002. Rho GTPases in transformation and metastasis.
 
Adv. Cancer Res.
 
 84:57–80.
Jo, M., K.S. Thomas, A.V. Somlyo, A.P. Somlyo, and S.L. Gonias. 2002. Cooper-
ativity between the Ras-ERK and Rho-Rho kinase pathways in urokinase-
type plasminogen activator-stimulated cell migration. 
 
J. Biol. Chem.
 
 277:
12479–12485.
Jones, G.E. 2000. Cellular signaling in macrophage migration and chemotaxis. 
 
J.
Leukoc. Biol.
 
 68:593–602.
Kjoller, L., and A. Hall. 2001. Rac mediates cytoskeletal rearrangements and in-
creased cell motility induced by urokinase-type plasminogen activator recep-
tor binding to vitronectin. 
 
J. Cell Biol.
 
 152:1145–1157.
Mazar, A.P. 2001. The urokinase plasminogen activator receptor (uPAR) as a tar-
get for the diagnosis and therapy of cancer. 
 
Anticancer Drugs.
 
 12:387–400.
Moore, M.A.S. 2001. The role of chemoattraction in cancer metastases. 
 
Bioessays.
 
23:674–676.
Muller, A., B. Homey, H. Soto, N.F. Ge, D. Catron, M.E. Buchanan, T. Mc-
Clanahan, E. Murphy, W. Yuan, S.N. Wagner, et al. 2001. Involvement of
chemokine receptors in breast cancer metastasis. 
 
Nature.
 
 410:50–56.
Nguyen, D.H., A.D. Catling, D.J. Webb, M. Sankovic, L.A. Walker, A.V. Som-
lyo, M.J. Weber, and S.L. Gonias. 1999. Myosin light chain kinase func-
tions downstream of Ras/ERK to promote migration of urokinase-type plas-
minogen activator-stimulated cells in an integrin-selective manner. 
 
J. Cell
Biol.
 
 146:149–164.
Nobes, C.D., and A. Hall. 1995. Rho, Rac, and Cdc42 Gtpases regulate the assem-
bly of multimolecular focal complexes associated with actin stress fibers,
lamellipodia, and filopodia. 
 
Cell.
 
 81:53–62.
Ossowski, L., and J.A. Aguirre-Ghiso. 2000. Urokinase receptor and integrin part-
nership: coordination of signaling for cell adhesion, migration and growth.
 
Curr. Opin. Cell Biol.
 
 12:613–620.
Parent, C.A., and P.N. Devreotes. 1999. A cell’s sense of direction. 
 
Science.
 
 284:
765–770.
Pepper, M.S. 2001. Role of the matrix metalloproteinase and plasminogen activa-
tor-plasmin systems in angiogenesis. 
 
Arterioscler Thromb. Vasc. Biol.
 
 21:
1104–1117.
Preissner, K.T., S.M. Kanse, and A.E. May. 2000. Urokinase receptor: a molecular
organizer in cellular communication. 
 
Curr. Opin. Cell Biol.
 
 12:621–628.
Rivera-Calzada, A., D. Robertson, J.R. MacFayden, J. Boskovic, C.M. Isacke, and
O. Llorca. 2003. Three-dimensional interplay among the ligand binding do-
mains of the uPAR-associated protein, Endo180. 
 
EMBO Rep.
 
 4:807–812.
 
Sahai, E., and C.J. Marshall. 2002. Rho-GTPases and cancer. 
 
Nat. Rev. Cancer.
 
2:133–142.
Schnack Nielsen, B., F. Rank, L.H. Engelholm, A. Holm, K. Dano, and N. Beh-
rendt. 2002. Urokinase receptor-associated protein (uPARAP) is expressed
in connection with malignant as well as benign lesions of the human breast
and occurs in specific populations of stromal cells. 
 
Int. J. Cancer.
 
 98:656–
664.
Sheikh, H., H. Yarwood, A. Ashworth, and C.M. Isacke. 2000. Endo180, an en-
docytic recycling glycoprotein related to the macrophage mannose receptor
is expressed on fibroblasts, endothelial cells and macrophages and functions
as a lectin receptor. 
 
J. Cell Sci.
 
 113:1021–1032.
St. Croix, B., C. Rago, V. Velculescu, G. Traverso, K.E. Romans, E. Montgomery,
A. Lal, G.J. Riggins, C. Lengauer, B. Vogelstein, and K.W. Kinzer. 2000.
Genes expressed in human tumor endothelium. 
 
Science
 
. 289:1197–1202.
Sturge, J., J. Hamelin, and G.E. Jones. 2002. N-WASP activation by a beta 1-inte-
grin-dependent mechanism supports P13K-independent chemotaxis stimu-
lated by urokinase-type plasminogen activator. 
 
J. Cell Sci.
 
 115:699–711.
Weiner, O.D. 2002. Regulation of cell polarity during eukaryotic chemotaxis: the
chemotactic compass. 
 
Curr. Opin. Cell Biol.
 
 14:196–202.
Wienke, D., J.R. MacFayden, and C.M. Isacke. 2003. Identification and character-
isation of the endocytic transmembrane glycoprotein Endo180 as a novel
collagen receptor. 
 
Mol. Biol. Cell.
 
 In press.
